AU2003300076C1 - Drug delivery from rapid gelling polymer composition - Google Patents

Drug delivery from rapid gelling polymer composition Download PDF

Info

Publication number
AU2003300076C1
AU2003300076C1 AU2003300076A AU2003300076A AU2003300076C1 AU 2003300076 C1 AU2003300076 C1 AU 2003300076C1 AU 2003300076 A AU2003300076 A AU 2003300076A AU 2003300076 A AU2003300076 A AU 2003300076A AU 2003300076 C1 AU2003300076 C1 AU 2003300076C1
Authority
AU
Australia
Prior art keywords
sulfhydryl
drug
composition
inhibitor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003300076A
Other languages
English (en)
Other versions
AU2003300076A1 (en
AU2003300076B2 (en
Inventor
Leanne Embree
David M. Gravett
Arpita Maiti
Aniko Takacs-Cox
Philip M. Toleikis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiotech International AG
Original Assignee
Angiotech International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiotech International AG filed Critical Angiotech International AG
Publication of AU2003300076A1 publication Critical patent/AU2003300076A1/en
Application granted granted Critical
Publication of AU2003300076B2 publication Critical patent/AU2003300076B2/en
Publication of AU2003300076C1 publication Critical patent/AU2003300076C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/041—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/145—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Colloid Chemistry (AREA)
AU2003300076A 2002-12-30 2003-12-30 Drug delivery from rapid gelling polymer composition Ceased AU2003300076C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43747102P 2002-12-30 2002-12-30
US60/437,471 2002-12-30
US44087503P 2003-01-17 2003-01-17
US60/440,875 2003-01-17
PCT/US2003/041580 WO2004060346A2 (en) 2002-12-30 2003-12-30 Drug delivery from rapid gelling polymer composition

Publications (3)

Publication Number Publication Date
AU2003300076A1 AU2003300076A1 (en) 2004-07-29
AU2003300076B2 AU2003300076B2 (en) 2009-07-30
AU2003300076C1 true AU2003300076C1 (en) 2010-03-04

Family

ID=32717905

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003300076A Ceased AU2003300076C1 (en) 2002-12-30 2003-12-30 Drug delivery from rapid gelling polymer composition

Country Status (8)

Country Link
US (3) US20040225077A1 (enExample)
EP (2) EP1594459B1 (enExample)
JP (2) JP2006516548A (enExample)
AT (1) ATE457716T1 (enExample)
AU (1) AU2003300076C1 (enExample)
CA (1) CA2511521C (enExample)
DE (1) DE60331367D1 (enExample)
WO (1) WO2004060346A2 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US7883500B2 (en) * 2003-03-26 2011-02-08 G&L Consulting, Llc Method and system to treat and prevent myocardial infarct expansion
RU2005133199A (ru) * 2003-03-28 2006-02-10 Козан Байосайенсиз, Инк. (Us) Устройства, способы и композиции для предупреждения рестеноза
WO2005046746A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
WO2005051871A2 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
WO2005089472A2 (en) * 2004-03-17 2005-09-29 Genzyme Corporation Anti-adhesion spraying
AU2005248294A1 (en) 2004-04-07 2005-12-08 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
US8034796B2 (en) * 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
US7201918B2 (en) * 2004-11-16 2007-04-10 Microvention, Inc. Compositions, systems and methods for treatment of defects in blood vessels
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
WO2006122414A1 (en) * 2005-05-17 2006-11-23 Matregen Corp. Depot for sustained and controlled delivery of methotrexate
US20070100199A1 (en) * 2005-11-03 2007-05-03 Lilip Lau Apparatus and method of delivering biomaterial to the heart
WO2007123993A2 (en) * 2006-04-19 2007-11-01 University Of South Florida Niosome-hydrogel drug delivery
EP2034906A4 (en) * 2006-06-21 2010-07-28 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR CONNECTING NON-ASSOCIATED LUMENS
US7732190B2 (en) * 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US20090148502A1 (en) * 2006-10-23 2009-06-11 Hemo Nanoscience, Llc Compositions and methods for treating lacerations, abrasions, avulsions, burns, ulcers, and cases of excessive bleeding
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8192760B2 (en) * 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US9474833B2 (en) 2006-12-18 2016-10-25 Cook Medical Technologies Llc Stent graft with releasable therapeutic agent and soluble coating
KR20120106880A (ko) 2007-01-21 2012-09-26 헤모텍 아게 체강의 협착 치료 및 급성 재협착 예방을 위한 의료 제품
DK2136850T3 (da) * 2007-04-13 2012-04-10 Kuros Biosurgery Ag Polymervævforsegling
US20080287633A1 (en) * 2007-05-18 2008-11-20 Drumheller Paul D Hydrogel Materials
US20080293910A1 (en) * 2007-05-24 2008-11-27 Tyco Healthcare Group Lp Adhesive formulatiions
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
CN101338036B (zh) * 2007-07-06 2010-11-03 常州百瑞吉生物医药有限公司 生物相容快速凝胶化水凝胶及其喷雾剂的制备方法
WO2009052376A1 (en) 2007-10-18 2009-04-23 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US10046081B2 (en) 2008-04-11 2018-08-14 The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc. Electrospun dextran fibers and devices formed therefrom
EP2276879B1 (en) 2008-04-11 2015-11-25 Virginia Commonwealth University Electrospun dextran fibers and devices formed therefrom
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2010057006A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20120122949A1 (en) * 2008-12-19 2012-05-17 The University Of Tokyo Ultra-high strength injectable hydrogel and process for producing the same
EP2451496B1 (en) 2009-07-10 2015-07-22 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
WO2011008393A2 (en) 2009-07-17 2011-01-20 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
CA2730598C (en) * 2010-03-16 2018-03-13 Confluent Surgical, Inc. Modulating drug release rate by controlling the kinetics of the ph transition in hydrogels
KR101782791B1 (ko) * 2010-09-02 2017-09-28 니폰 가야꾸 가부시끼가이샤 약물-블록 코폴리머 복합체와 그것을 함유하는 의약의 제조방법
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
KR101255337B1 (ko) * 2010-10-04 2013-04-16 한국과학기술연구원 온도 감응성 합성 고분자를 이용한 일산화질소 전달체
JP5998201B2 (ja) 2011-04-20 2016-09-28 カービラン セラピューティクス， インコーポレイテッド Ｉｎ−ｓｉｔｕゲル形成組成物
EP2541547A1 (en) 2011-06-30 2013-01-02 Thomson Licensing Method and apparatus for changing the relative positions of sound objects contained within a higher-order ambisonics representation
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US8936784B2 (en) * 2011-10-17 2015-01-20 Poly-Med, Inc. Absorbable in situ gel-forming system, method of making and use thereof
US9597425B2 (en) 2011-10-18 2017-03-21 St. Teresa Medical, Inc. Method of forming a hemostatic product
US10849879B2 (en) * 2011-10-19 2020-12-01 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
WO2013086419A1 (en) * 2011-12-09 2013-06-13 California Institute Of Technology Polymer scaffolds and their use in the treatment of vision loss
US9758671B2 (en) * 2012-07-31 2017-09-12 Matthew Becker Strain-promoted crosslinking of PEG-based hydrogels via copper-free cycloaddition
US10016454B2 (en) * 2012-12-04 2018-07-10 Cohera Medical, Inc. Silane-containing moisture-curable tissue sealant
TWI624270B (zh) * 2013-01-17 2018-05-21 財團法人工業技術研究院 藥物組合物
US9987391B2 (en) 2013-03-13 2018-06-05 St. Jude Medical Coordination Center Bvba Injectable hydrogels
CA2922991A1 (en) 2013-11-12 2015-05-21 St. Teresa Medical, Inc. Hemostatic products
JP2015137430A (ja) * 2014-01-20 2015-07-30 国立大学法人福井大学 ゲル繊維およびその不織布
US9522114B1 (en) 2014-03-27 2016-12-20 University Of South Florida Enhanced targeted drug delivery system via chitosan hydrogel and chlorotoxin
JP6573873B2 (ja) * 2014-04-17 2019-09-11 典穂 神谷 ハイドロゲルの製造方法、包括対象物の包括方法、および包括対象物の放出方法
US12006395B2 (en) * 2015-01-02 2024-06-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Biodegradable polymer
WO2017019214A1 (en) 2015-07-29 2017-02-02 Musc Foundation For Research Development Donor organ pre-treatment formulation
US10080806B2 (en) 2015-08-19 2018-09-25 International Business Machines Corporation Sulfur-containing polymers from hexahydrotriazine and dithiol precursors as a carrier for active agents
US9550863B1 (en) 2015-10-05 2017-01-24 International Business Machines Corporation Polymers from stabilized imines
US9534084B1 (en) 2015-11-02 2017-01-03 International Business Machines Corporation High molecular weight polythioaminals from a single monomer
EP3373853A4 (en) 2015-11-12 2019-07-10 St. Teresa Medical, Inc. METHOD FOR SEALING A DUROTOMY
US9862802B2 (en) 2015-11-30 2018-01-09 International Business Machines Corporation Poly(thioaminal) probe based lithography
US10227444B2 (en) 2016-06-01 2019-03-12 International Business Machines Corporation Degradable polyurethanes containing thioaminal groups
WO2019089717A1 (en) 2017-11-02 2019-05-09 St. Teresa Medical, Inc. Fibrin sealant products
WO2019152917A1 (en) 2018-02-02 2019-08-08 Galen Therapeutics Llc Apparatus and method for protecting neurons and reducing inflammation and scarring
EP3768236A1 (en) * 2018-03-20 2021-01-27 Dana-Farber Cancer Institute, Inc. Compositions and methods for cancer treatment
WO2019195728A1 (en) * 2018-04-06 2019-10-10 University Of Notre Dame Du Lac Refillable drug delivery by affinity homing
CN110960507B (zh) * 2018-09-30 2022-03-18 复旦大学 低分子量肝素和天然药物前药构成的磷酸钙-脂质纳米药物共递送系统
CN111467322B (zh) * 2020-04-08 2022-03-04 南方医科大学南方医院 Vb12靶向型西地那非纳米药物的合成方法及应用
CN113181418B (zh) * 2021-04-09 2022-05-03 青岛大学附属医院 一种医用粘合剂及其制备方法
CN115068668B (zh) * 2022-06-08 2023-05-09 湖南工业大学 一种核壳结构多孔水凝胶栓塞微球及其制备方式
US20240066052A1 (en) * 2022-08-30 2024-02-29 Ethicon, Inc. Biodegradable lung sealants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062827A2 (en) * 1999-04-16 2000-10-26 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition

Family Cites Families (660)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3387001A (en) 1964-10-19 1968-06-04 Lilly Co Eli Novel aminoacyl esters of desacetyl vincaleukoblastine
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (enExample) * 1967-12-20 1972-03-06 Pharmacia Ab
US3742955A (en) * 1970-09-29 1973-07-03 Fmc Corp Fibrous collagen derived product having hemostatic and wound binding properties
US3894000A (en) 1971-01-27 1975-07-08 Upjohn Co Ara-cytidine derivatives and process of preparation
US4066650A (en) 1971-02-11 1978-01-03 Egyud Laszlo G Keto-aldehyde-amine addition products and method of making same
CA955937A (en) 1971-06-28 1974-10-08 Shionogi And Co. Ltd. Cyclic phosphamide derivatives
US3810473A (en) * 1972-12-04 1974-05-14 Avicon Inc Liquid-laid, non-woven, fibrous collagen derived surgical web having hemostatic and wound sealing properties
US3876501A (en) * 1973-05-17 1975-04-08 Baxter Laboratories Inc Binding enzymes to activated water-soluble carbohydrates
US3991045A (en) 1973-05-30 1976-11-09 Asahi Kasei Kogyo Kabushiki Kaisha N4 -acylarabinonucleosides
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2360794C2 (de) * 1973-12-06 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung von Peptiden
FR2287910A1 (fr) 1974-10-15 1976-05-14 Asahi Chemical Ind Derives nucleotidiques et procede de preparation de ceux-ci
US4012390A (en) 1974-10-16 1977-03-15 Eli Lilly And Company Vinblastinoic acid
US3949073A (en) * 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
US4279817A (en) 1975-05-30 1981-07-21 The United States Of America As Represented By The Department Of Health & Human Services Method for producing dimer alkaloids
CH596313A5 (enExample) * 1975-05-30 1978-03-15 Battelle Memorial Institute
IL47468A (en) * 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
US4233360A (en) 1975-10-22 1980-11-11 Collagen Corporation Non-antigenic collagen and articles of manufacture
US4488911A (en) 1975-10-22 1984-12-18 Luck Edward E Non-antigenic collagen and articles of manufacture
US4057548A (en) 1975-11-11 1977-11-08 Jacek Wiecko Process for preparing methotrexate or an N-substituted derivative thereof and/or a di (lower) alkyl ester thereof and precursor therefor
JPS5289680A (en) 1976-01-22 1977-07-27 Mitsui Toatsu Chem Inc Preparation of 1-(2-tetrahydrofuryl)-5-flurouracil
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
AT352867B (de) * 1976-05-12 1979-10-10 Battelle Institut E V Knochenersatz-knochenverbund-oder prothesen- verankerungswerkstoff und verfahren zu seiner herstellung
DE2623420C2 (de) 1976-05-25 1978-07-06 Stiftung Deutsches Krebsforschungszentrum, 6900 Heidelberg Verfahren zur Herstellung unsymmetrisch 13-disubstituierter Nitrosoharnstoffe
US4258052A (en) 1976-08-17 1981-03-24 Yu Ruey J Treatment of psoriasis with nicotinamide analogues
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
USRE30561E (en) 1976-12-06 1981-03-31 Eli Lilly And Company Vinca alkaloid intermediates
JPS5395917A (en) 1977-02-03 1978-08-22 Tokyo Tanabe Co Process for preparing nitrosourea derivative of glucopyranose
JPS53149985A (en) 1977-05-31 1978-12-27 Asahi Chem Ind Co Ltd Preparation of 5-fluorouracil derivatives
US4164559A (en) * 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
SE7903361L (sv) 1978-04-20 1979-10-21 Johnson Matthey Co Ltd Kompositioner innehallande platina
US4404970A (en) * 1978-05-19 1983-09-20 Sawyer Philip Nicholas Hemostatic article and methods for preparing and employing the same
US4390519A (en) * 1978-05-19 1983-06-28 Sawyer Philip Nicholas Bandage with hemostatic agent and methods for preparing and employing the same
US4238480A (en) 1978-05-19 1980-12-09 Sawyer Philip Nicholas Method for preparing an improved hemostatic agent and method of employing the same
US4215062A (en) 1978-05-22 1980-07-29 University Of Kansas Endowment Association Anthracycline synthesis
US4296105A (en) 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4259242A (en) 1978-10-10 1981-03-31 Eli Lilly And Company Method of preparing vindesine sulfate
JPS5559173A (en) 1978-10-27 1980-05-02 Kaken Pharmaceut Co Ltd Novel fluorouracil derivative
US4210584A (en) 1979-01-15 1980-07-01 Eli Lilly And Company Vindesine synthesis
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4412947A (en) 1979-09-12 1983-11-01 Seton Company Collagen sponge
US4279812A (en) * 1979-09-12 1981-07-21 Seton Company Process for preparing macromolecular biologically active collagen
US4371540A (en) 1979-09-14 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroimidazoles of low toxicity and high activity as radiosensitizers of hypoxic tumor cells
DE2943520C2 (de) * 1979-10-27 1982-05-19 Fa. Carl Freudenberg, 6940 Weinheim Verfahren zur Herstellung von Kollagenschwamm für medizinische oder kosmetische Zwecke
US4639456A (en) 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
US4374414A (en) 1980-06-26 1983-02-15 Gte Automatic Electric Labs Inc. Arbitration controller providing for access of a common resource by a duplex plurality of central processing units
CS216992B1 (en) * 1980-07-21 1982-12-31 Miroslav Stol Composite polymere material for the biological and medicinal utilitation and method of preparation thereof
US4299778A (en) 1980-07-21 1981-11-10 Shell Oil Company N'Cyclopropyl-N-(fluorophenyl)-N-hydroxyureas
JPS5929199B2 (ja) 1980-08-25 1984-07-18 一丸フアルコス株式会社 脂溶性シルクペプタイドの製造法
US4314380A (en) * 1980-09-26 1982-02-09 Koken Co., Ltd. Artificial bone
US4367239A (en) 1980-09-29 1983-01-04 Kefalas A/S Nitrosourea derivatives, pharmaceutical compositions thereof and method of preparation
US4301277A (en) 1980-10-20 1981-11-17 Sri International 3-Deamino-3-(4-morpholinyl) derivatives of daunorubicin and doxorubicin
JPS5775993A (en) 1980-10-30 1982-05-12 Tetsuo Suami Novel nitrosourea derivative and its preparation
JPS6041078B2 (ja) 1980-11-05 1985-09-13 日新製糖株式会社 ゲンチアノ−スニトロソ尿素誘導体
US4415665A (en) 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
US4314054A (en) 1981-03-23 1982-02-02 Sri International 3'-Deamino-3'-(4-methoxy-1-piperidinyl) derivatives of daunorubicin and doxorubicin
US4494547A (en) 1981-03-30 1985-01-22 North Carolina Central University 2H-isoindolediones, their synthesis and use as radiosensitizers
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4375432A (en) 1981-05-12 1983-03-01 Eli Lilly And Company Method of preparing vincristine
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4451568A (en) * 1981-07-13 1984-05-29 Battelle Memorial Institute Composition for binding bioactive substances
US4357274A (en) 1981-08-06 1982-11-02 Intermedicat Gmbh Process for the manufacture of sclero protein transplants with increased biological stability
US4415628A (en) 1981-10-26 1983-11-15 Seton Company Moisture vapor permeable sheet materials
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4424208A (en) * 1982-01-11 1984-01-03 Collagen Corporation Collagen implant material and method for augmenting soft tissue
US4462992A (en) 1982-02-08 1984-07-31 Research Corporation Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof
US4582640A (en) * 1982-03-08 1986-04-15 Collagen Corporation Injectable cross-linked collagen implant material
US4578067A (en) * 1982-04-12 1986-03-25 Alcon (Puerto Rico) Inc. Hemostatic-adhesive, collagen dressing for severed biological surfaces
JPS58180162A (ja) 1982-04-19 1983-10-21 株式会社高研 抗血栓性医用材料
US4544516A (en) * 1982-07-28 1985-10-01 Battelle Development Corporation Collagen orientation
US4737544A (en) * 1982-08-12 1988-04-12 Biospecific Technologies, Inc. Biospecific polymers
US4973493A (en) 1982-09-29 1990-11-27 Bio-Metric Systems, Inc. Method of improving the biocompatibility of solid surfaces
US4585859A (en) 1983-05-24 1986-04-29 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
JPS59219300A (ja) 1983-05-27 1984-12-10 Nisshin Seito Kk シヨ糖ニトロソ尿素誘導体
JPS6028936A (ja) * 1983-07-27 1985-02-14 Koken:Kk アテロコラ−ゲン水溶液およびその製造方法
US4563351A (en) * 1983-08-01 1986-01-07 Forsyth Dental Infirmary For Children Self-gelling therapeutic compositions for topical application
US4902791A (en) 1983-08-30 1990-02-20 Sanofi S.A. Nitrosourea derivatives, process for their preparation and medicaments containing them
US4490529A (en) 1983-09-06 1984-12-25 Dana-Farber Cancer Institute, Inc. Cysteic acid and homocysteic acid analogues of methotrexate and aminopterin
US4894364A (en) 1983-10-26 1990-01-16 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US4515637A (en) * 1983-11-16 1985-05-07 Seton Company Collagen-thrombin compositions
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
MX163953B (es) * 1984-03-27 1992-07-03 Univ New Jersey Med Procedimiento para preparar una matriz biodegradable a base de colageno
JPS6110511A (ja) 1984-06-26 1986-01-18 Sumitomo Chem Co Ltd 低酸素細胞放射線増感剤
US4789663A (en) 1984-07-06 1988-12-06 Collagen Corporation Methods of bone repair using collagen
US4681091A (en) 1984-08-03 1987-07-21 Picker Donald H Combination modality cancer therapy
JPS6145765A (ja) * 1984-08-07 1986-03-05 宇部興産株式会社 血管補綴物及びその製造方法
US4553974A (en) 1984-08-14 1985-11-19 Mayo Foundation Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor
US4687820A (en) * 1984-08-22 1987-08-18 Cuno Incorporated Modified polypeptide supports
US4557764A (en) 1984-09-05 1985-12-10 Collagen Corporation Process for preparing malleable collagen and the product thereof
US4563350A (en) * 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US4588831A (en) 1984-11-09 1986-05-13 Natec Platinum complex compounds of substituted 5,8-dihydroxyl-1,4-naphthoquinone, and process for their production and use
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4600533A (en) * 1984-12-24 1986-07-15 Collagen Corporation Collagen membranes for medical use
SU1261253A1 (ru) 1984-12-27 1990-10-07 Отделение Института химической физики АН СССР Оксоаммониевые производные нитрозомочевины, про вл ющие противоопухолевую активность, и способ их получени
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPS61167616A (ja) 1985-01-22 1986-07-29 Adeka Argus Chem Co Ltd 放射線増感剤
US4841045A (en) 1985-03-12 1989-06-20 University Of Vermont & State Agricultural College Synthesis of vinblastine and vincristine type compounds
US4642117A (en) * 1985-03-22 1987-02-10 Collagen Corporation Mechanically sheared collagen implant material and method
CA1260391A (en) * 1985-03-28 1989-09-26 Karl A. Piez Xenogeneic collagen/mineral preparations in bone repair
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
FR2582651B1 (fr) 1985-06-03 1987-08-28 Pf Medicament Procede de preparation de vincristine
DE3521684A1 (de) * 1985-06-18 1986-12-18 Dr. Müller-Lierheim KG, Biologische Laboratorien, 8033 Planegg Verfahren zur beschichtung von polymeren
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS6230768A (ja) 1985-08-01 1987-02-09 Taisho Pharmaceut Co Ltd イミダゾ−ル誘導体
JPS6230777A (ja) 1985-08-01 1987-02-09 Taisho Pharmaceut Co Ltd イミダゾ−ル誘導体
JPH0720864B2 (ja) 1985-08-15 1995-03-08 旭電化工業株式会社 放射線増感剤
JPH0723308B2 (ja) 1985-12-12 1995-03-15 旭電化工業株式会社 放射線増感剤
US4851513A (en) * 1985-09-06 1989-07-25 Minnesota Mining And Manufacturing Company Viscoelastic collagen solution for opthalmic use and method of preparation
SU1336489A1 (ru) 1985-10-24 1990-02-15 Отделение Института химической физики АН СССР Способ получени нитроксильных производных нитрозомочевины общей формулы
JPH0717518B2 (ja) 1985-11-28 1995-03-01 湧永製薬株式会社 制ガン作用調節剤
EP0232693A3 (fr) 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
WO1987004078A1 (en) 1986-01-06 1987-07-16 The University Of Melbourne Precipitation of collagen in tactoid form
US4774227A (en) * 1986-02-14 1988-09-27 Collagen Corporation Collagen compositions for bone repair containing autogeneic marrow
US4983580A (en) * 1986-04-04 1991-01-08 Allergan, Inc. Methods and materials for use in corneal wound healing
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US4841085A (en) 1986-06-30 1989-06-20 Board Of Regents, University Of Texas System Aldophosphamides
US6432919B1 (en) 1986-07-01 2002-08-13 Genetics Institute, Inc. Bone morphogenetic protein-3 and compositions
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US5004606A (en) 1986-09-24 1991-04-02 Hybritech Incorporated Non-covalent antibody-anthracycline immunocomplexes
US5616584A (en) 1986-09-25 1997-04-01 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US4979959A (en) 1986-10-17 1990-12-25 Bio-Metric Systems, Inc. Biocompatible coating for solid surfaces
JPS63170375A (ja) 1987-01-07 1988-07-14 Pola Chem Ind Inc ヘテロ環化合物誘導体、その製造法およびこれを有効成分とする放射線増感剤
US5047528A (en) 1987-01-22 1991-09-10 University Of Bristish Columbia Process of synthesis of vinblastine and vincristine
GB8701381D0 (en) 1987-01-22 1987-02-25 Erba Farmitalia Antitumor agent
FR2611203B1 (fr) 1987-02-20 1989-06-09 Sturtz Georges Analogues gem-diphosphoniques d'amethopterine (methotrexate) et de derives deaza-n-10 amethopterine. leur preparation et les compositions pharmaceutiques qui les contiennent
US5034320A (en) 1987-03-31 1991-07-23 Allelix, Inc. Vinblastine synthesis
US4921963A (en) 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
HU199492B (en) 1987-05-08 1990-02-28 Sankyo Co Process for producing antitumour platinum complexes and pharmaceutical compositions comprising same
JPS63310873A (ja) 1987-06-09 1988-12-19 Taiho Yakuhin Kogyo Kk ４，５−ジニトロイミダゾ−ル誘導体
JP2602887B2 (ja) 1987-06-10 1997-04-23 京都大学長 新規含フッ素３−ニトロ−１，２，４−トリアゾールおよびそれを含む放射線増感剤
US5304654A (en) 1987-06-10 1994-04-19 Yasunori Nishijima Fluorine-containing nitroimidazole compounds
CA1329206C (en) 1987-06-10 1994-05-03 Tsutomu Kagiya Fluorine-containing nitroazole derivatives and radiosensitizer comprising the same
US4797397A (en) 1987-07-31 1989-01-10 Warner-Lambert Company 2-nitroimidazole derivatives useful as radiosensitizers for hypoxic tumor cells
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
JPH01139596A (ja) 1987-11-25 1989-06-01 Pola Chem Ind Inc ヘテロ環化合物誘導体、その製造法並びにこれを有効成分とする放射線増感剤、抗ウイルス剤及び抗癌剤
US4996152A (en) 1987-12-04 1991-02-26 The United States Of America, As Represented By The Secretary Of Agriculture Avian herpesvirus amplicon as a eucaryotic expression vector
US5364622A (en) 1987-12-04 1994-11-15 Dr. Karl Thomae Gmbh Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
US4950699A (en) * 1988-01-11 1990-08-21 Genetic Laboratories, Inc. Wound dressing incorporating collagen in adhesive layer
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5192316A (en) * 1988-02-16 1993-03-09 Allergan, Inc. Ocular device
US5024742A (en) * 1988-02-24 1991-06-18 Cedars-Sinai Medical Center Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US4923876A (en) 1988-04-18 1990-05-08 Cetus Corporation Vinca alkaloid pharmaceutical compositions
US5290552A (en) * 1988-05-02 1994-03-01 Matrix Pharmaceutical, Inc./Project Hear Surgical adhesive material
US5190929A (en) 1988-05-25 1993-03-02 Research Corporation Technologies, Inc. Cyclophosphamide analogs useful as anti-tumor agents
US4908356A (en) 1988-05-25 1990-03-13 Research Corporation Technologies, Inc. Aldophosphamide derivatives useful as antitumor agents
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5167960A (en) 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
US4906460A (en) 1988-08-05 1990-03-06 Sorenco Additive for hair treatment compositions
US5665583A (en) 1988-08-12 1997-09-09 Arch Dev Corp Methods and materials relating to IMPDH and GMP production
US5066658A (en) 1988-11-10 1991-11-19 Ortho Pharmaceutical Corporation Substituted hydroxyureas
US5936035A (en) * 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5304595A (en) 1988-11-21 1994-04-19 Collagen Corporation Collagen-polymer conjugates
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5475052A (en) 1988-11-21 1995-12-12 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5264214A (en) 1988-11-21 1993-11-23 Collagen Corporation Composition for bone repair
US5109112A (en) 1989-01-19 1992-04-28 Merck & Co., Inc. FK-506 cytosolic binding protein
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69033982T2 (de) 1989-03-21 2002-10-24 The United States Of America, Represented By The Secretary Matrizenmetalloproteinase-inhibitor-peptide
DE69019410T2 (de) 1989-03-31 1995-10-05 Canji Inc Retinoblastoma-Genprodukt-Antikörper und deren Verwendungen.
US5641764A (en) 1989-03-31 1997-06-24 Peter Maccallum Institute Halogenated DNA ligand radiosensitizers for cancer therapy
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5141747A (en) * 1989-05-23 1992-08-25 Minnesota Mining And Manufacturing Company Denatured collagen membrane
US5200411A (en) 1989-06-14 1993-04-06 Sandoz, Ltd. Heteroatoms-containing tricyclic compounds
DE3924424A1 (de) 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
US5100885A (en) 1989-08-01 1992-03-31 Johnson Matthey, Inc. Copper radiosensitizers
NZ234718A (en) * 1989-08-11 1992-05-26 Saint Gobain Isover Decomposable glass fibres
US5166149A (en) 1989-09-08 1992-11-24 Chemex Pharmaceuticals, Inc. Methotrexate compositions and methods of treatment using same
DE69028610T2 (de) 1989-12-19 1997-02-06 Pharmacia S.P.A., Mailand/Milano Chirale 1,5-diiodo-2-methoxy oder benzyloxy Zwischenprodukte
JP2626727B2 (ja) 1990-01-26 1997-07-02 ポーラ化成工業株式会社 ２―ニトロイミダゾール誘導体、その製造法及びこれを有効成分とする放射線増感剤
US5104957A (en) 1990-02-28 1992-04-14 Autogenesis Technologies, Inc. Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom
US5201764A (en) * 1990-02-28 1993-04-13 Autogenesis Technologies, Inc. Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom
US5989894A (en) 1990-04-20 1999-11-23 University Of Wyoming Isolated DNA coding for spider silk protein, a replicable vector and a transformed cell containing the DNA
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5688678A (en) 1990-05-16 1997-11-18 Genetics Institute, Inc. DNA encoding and methods for producing BMP-8 proteins
US5594158A (en) 1990-06-22 1997-01-14 The Board Of Regents Of The University Of Nebraska Processes for producing doxorubicin, daunomycinone, and derivatives of doxorubicin
US5210030A (en) 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
CA2086334A1 (en) 1990-06-29 1991-12-30 The Regents Of The University Of Michigan Neurofibromatosis gene
US5147652A (en) 1990-07-03 1992-09-15 Cell Research Corporation Autobiotics and their use in eliminating nonself cells in vivo
US5209776A (en) * 1990-07-27 1993-05-11 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
SE466754B (sv) * 1990-09-13 1992-03-30 Berol Nobel Ab Saett att kovalent binda biopolymerer till hydrofila ytor
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5198421A (en) 1991-04-26 1993-03-30 Merck & Co., Inc. Phosphorylated cyclic lipopeptide
US5626863A (en) * 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5380536A (en) 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
US5169754A (en) 1990-10-31 1992-12-08 Coulter Corporation Biodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making same
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5183900A (en) 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
WO1993013663A1 (en) 1992-01-17 1993-07-22 Abbott Laboratories Method of directing biosynthesis of specific polyketides
US5116756A (en) 1991-01-28 1992-05-26 Merck & Co., Inc. Process for producing FK-506
US5219895A (en) * 1991-01-29 1993-06-15 Autogenesis Technologies, Inc. Collagen-based adhesives and sealants and methods of preparation and use thereof
US5294715A (en) 1991-02-01 1994-03-15 University Of Pittsburgh Acridine-intercalator based hypoxia selective cytotoxins
US5156613A (en) * 1991-02-13 1992-10-20 Interface Biomedical Laboratories Corp. Collagen welding rod material for use in tissue welding
GB9103430D0 (en) 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5147877A (en) 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5091389A (en) 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5093338A (en) 1991-04-23 1992-03-03 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5140018A (en) 1991-05-07 1992-08-18 Abbott Laboratories 1,3,2-benzodithiazole-1-oxide compounds
US5889169A (en) 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US5225403A (en) 1991-06-25 1993-07-06 Merck & Co., Inc. C-21 hydroxylated FK-506 antagonist
CA2108770C (en) 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
CA2071160A1 (en) 1991-07-31 1993-02-01 Vittorio Farina Asymmetric synthesis of taxol side chain
US5256657A (en) 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
US5534632A (en) 1991-09-05 1996-07-09 Abbott Laboratories Macrocyclic carbamate immunomodulators
US5541193A (en) 1991-09-05 1996-07-30 Abbott Laboratories Heterocycle-containing macrocyclic immunomodulators
US5563172A (en) 1991-09-05 1996-10-08 Abbott Laboratories Macrocyclic amide and urea immunomodulators
KR100351222B1 (ko) 1991-09-05 2002-09-05 아보트 러보러터리즈 매크로사이클릭 면역 조절제 및 이의 제조방법
US5561137A (en) 1991-09-05 1996-10-01 Abbott Laboratories Thio-heterocyclic macrolactam immunomodulators
US5604234A (en) 1991-09-05 1997-02-18 Abbott Laboratories Substituted thiol macrolactam immunomodulators
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
SG46582A1 (en) 1991-09-23 1998-02-20 Univ Florida State 10-Desacetoxytaxol derivatives
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5837747A (en) 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
FR2683529B1 (fr) 1991-11-12 1994-02-04 Bretagne Occidentale Universite Composes pharmaceutiques gem-diphosphonates analogues du cis-platine.
US5164399A (en) 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
AU3140093A (en) 1991-11-22 1993-06-15 University Of Mississippi, The Synthesis and optical resolution of the taxol side chain and related compounds
NZ240785A (en) 1991-11-28 1995-08-28 Cancer Res Campaign Tech Substituted nitro aniline derivatives and medicaments
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
US5221625A (en) 1992-01-10 1993-06-22 Merck & Co., Inc. Cyclcic FR-900520 microbial biotransformation agent
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
WO1993018043A1 (en) 1992-03-05 1993-09-16 American Home Products Corporation Novel rapamycin 42-sulfonates and 42-(n-carboalkoxy)sulfamates useful as immunosuppressive agents
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5324634A (en) 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US5440056A (en) 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
EP0639982A1 (en) 1992-05-01 1995-03-01 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
AU4400593A (en) 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5254580A (en) 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
JPH08502082A (ja) 1992-07-02 1996-03-05 コラーゲン コーポレイション 生体適合性ポリマー結合体
US5385606A (en) 1992-07-06 1995-01-31 Kowanko; Nicholas Adhesive composition and method
ZA935110B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
US5324644A (en) 1992-07-28 1994-06-28 Merck & Co., Inc. Process for producing immunosuppressant agent
MX9304399A (es) 1992-07-31 1994-02-28 Warner Lambert Co Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
MX9304868A (es) 1992-08-13 1994-05-31 American Home Prod 27-hidroxirapamicina, derivados de la misma y composicion farmaceutica que la contiene.
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
US5318895A (en) 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
ZA938349B (en) 1992-11-10 1994-08-01 Smithkline Beecham Corp Rapamycin derivatives.
US5858679A (en) 1992-11-12 1999-01-12 Fornace, Jr.; Albert J. Method for determining the presence of functional p53 by measuring GADD45 protein expression
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5661033A (en) 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5380751A (en) 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
JPH06203767A (ja) 1992-12-28 1994-07-22 Matsushita Electron Corp 偏向ヨーク
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
GB9302016D0 (en) 1993-02-02 1993-03-17 Sandoz Ltd Compounds
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US6284513B1 (en) 1993-02-03 2001-09-04 Warner-Lambert Company Process for the production of stromelysin catalytic domain protein
GB9302569D0 (en) 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
US5310903A (en) 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
WO1994020089A1 (en) 1993-03-09 1994-09-15 Enzon, Inc. Taxol-based compositions with enhanced bioactivity
WO1994021253A1 (en) 1993-03-17 1994-09-29 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
US5457194A (en) 1993-03-17 1995-10-10 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
US5594006A (en) 1993-03-18 1997-01-14 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
US5382582A (en) 1993-03-26 1995-01-17 Chan; Carcy L. Methotrexate analogs and methods of using same
GB9307956D0 (en) 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
AU686629B2 (en) 1993-04-23 1998-02-12 Wyeth Rapamycin Conjugates and Antibodies
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5306727A (en) 1993-04-30 1994-04-26 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US5380897A (en) 1993-05-25 1995-01-10 Hoeschele; James D. Tri(platinum) complexes
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5549904A (en) * 1993-06-03 1996-08-27 Orthogene, Inc. Biological adhesive composition and method of promoting adhesion between tissue surfaces
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
WO1994029450A2 (en) 1993-06-15 1994-12-22 E.I. Du Pont De Nemours And Company Novel, recombinantly produced spider silk analogs
JPH07107058B2 (ja) 1993-06-22 1995-11-15 旭電化工業株式会社 ニトロトリアゾール化合物
US6080569A (en) 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
US6140087A (en) 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
DK0710233T3 (da) 1993-07-20 2000-01-03 Pfizer Heteroarylcycloalkenylhydroxyurinstoffer
GB9315914D0 (en) 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5773428A (en) 1993-08-05 1998-06-30 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
US6013792A (en) 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
GB9318612D0 (en) 1993-09-08 1993-10-27 Sandoz Ltd An assay
US5409915A (en) 1993-09-14 1995-04-25 The University Of Vermont And State Agricultural College Bis-platinum (IV) complexes as chemotherapeutic agents
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5455262A (en) 1993-10-06 1995-10-03 Florida State University Mercaptosulfide metalloproteinase inhibitors
US5470834A (en) 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US5650442A (en) 1993-10-08 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US6037472A (en) 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
GB9323165D0 (en) 1993-11-10 1994-01-05 Chiros Ltd Compounds
WO1995013375A1 (en) 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1995014023A1 (en) 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
WO1995015328A1 (en) 1993-11-30 1995-06-08 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
ES2146741T3 (es) 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
EP0740655B1 (en) 1994-01-22 1999-10-20 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5444072A (en) 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US5362735A (en) 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5514716A (en) 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.
US5395850A (en) 1994-03-10 1995-03-07 Bristol-Myers Squibb Company 6,7-epoxy paclitaxels
GB9405076D0 (en) 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
FI951367A7 (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
ATE386131T1 (de) 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
US5641636A (en) 1994-05-20 1997-06-24 University Of Pennsylvania Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity
US6140099A (en) 1994-05-20 2000-10-31 The Trustees Of The University Of Pennsylvania Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity
GB9411088D0 (en) 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US6022898A (en) 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5622866A (en) 1994-06-23 1997-04-22 Merck & Co., Inc. Expression cassettes useful in construction of integrative and replicative expression vectors for Streptomyces
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
MX9606494A (es) 1994-07-27 1997-03-29 Sandoz Ltd Compuestos organicos.
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
CZ288436B6 (en) 1994-10-05 2001-06-13 Darwin Discovery Ltd Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
IL115995A0 (en) 1994-11-15 1996-01-31 Bayer Ag Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
EP0713707A1 (en) 1994-11-23 1996-05-29 Collagen Corporation In situ crosslinkable, injectable collagen composition for tissue augmention
GB9423914D0 (en) 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5532265A (en) 1994-11-30 1996-07-02 The Board Of Trustees Of The Leland Stanford Junior University Treatment of central nervous system inflammatory disease with matrix metalloprotease inhibitors
US5639746A (en) 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5602142A (en) 1994-12-21 1997-02-11 Evanston Hospital Corporation DNA-affinic hypoxia selective cytotoxins
JP2902318B2 (ja) 1994-12-28 1999-06-07 呉羽化学工業株式会社 エスクレチン誘導体、その製造方法及びマトリックスメタロプロテアーゼ阻害剤
US6033847A (en) 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
US5672598A (en) 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5900245A (en) * 1996-03-22 1999-05-04 Focal, Inc. Compliant tissue sealants
AU709527B2 (en) 1995-03-23 1999-09-02 Board Of Regents, The University Of Texas System Redox and photoinitiator systems for priming for improved adherence of gels to substrates
JPH11502222A (ja) 1995-03-23 1999-02-23 キャンタブ ファーマシューティカルズ リサーチ リミティド 遺伝子供給用ベクター
US6025480A (en) 1995-04-03 2000-02-15 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecules encoding P57KIP2
US5691381A (en) 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
JP3156794B2 (ja) 1995-04-25 2001-04-16 富士薬品工業株式会社 高水溶性メタロプロテイナーゼ阻害剤
WO1996035712A1 (en) 1995-05-10 1996-11-14 Chiroscience Limited Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
AU701279B2 (en) 1995-05-10 1999-01-21 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and TNF liberation and their therapeutic uses
EP0824543A1 (en) 1995-05-10 1998-02-25 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
AU692102B2 (en) 1995-05-10 1998-05-28 Darwin Discovery Limited Peptidyl compounds and their therapeutic use
GB9509631D0 (en) 1995-05-12 1995-07-05 Sandoz Ltd Antifungal combination
JP3133642B2 (ja) 1995-05-19 2001-02-13 花王株式会社 毛髪化粧料
US5665764A (en) 1995-06-02 1997-09-09 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
US5627206A (en) 1995-06-02 1997-05-06 Warner-Lambert Company Tricyclic inhibitor of matrix metalloproteinases
US5886022A (en) 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5677282A (en) 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US5917090A (en) 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
GB9514867D0 (en) 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
AUPN477695A0 (en) 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
WO1997010502A1 (en) 1995-09-15 1997-03-20 Merck & Co., Inc. A high throughput assay using fusion proteins
US5723313A (en) 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5684152A (en) 1995-09-28 1997-11-04 Merck & Co., Inc. Preparation of carboxyalkyl derivatives as inhibitors of matrix metalloproteinases
US5665777A (en) 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
US5977141A (en) 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
US5830727A (en) 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system
AU711804B2 (en) 1995-11-23 1999-10-21 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5843903A (en) 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US6117633A (en) 1995-12-08 2000-09-12 University Technologies International Inc. DNA sequence encoding the tumor suppressor gene ING1
US5752974A (en) * 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
PT2111876E (pt) 1995-12-18 2011-12-23 Angiodevice Internat Gmbh Composições de polímero reticulado e seus métodos de utilização
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
PL327494A1 (en) 1995-12-22 1998-12-21 Warner Lambert Co Aromatic keto-carboxylic acids and their derivatives as inhibitors of matrix metalloproteinases
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
PT871439E (pt) 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US5744349A (en) 1996-03-05 1998-04-28 Washington University DNA sequences encoding human Myt1 kinase
GB9607120D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607119D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607249D0 (en) 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
WO1997038091A1 (en) 1996-04-10 1997-10-16 Sloan-Kettering Institute For Cancer Research METHODS FOR ENHANCING ANIMAL GROWTH AND CELL PROLIFERATION BY ELIMINATION OF FUNCTIONAL p27?Kip1¿
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
US6128582A (en) 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
US5925637A (en) 1997-05-15 1999-07-20 Bayer Corporation Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
US5863915A (en) 1996-05-15 1999-01-26 Bayer Corporation Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
US5968795A (en) 1996-05-15 1999-10-19 Bayer Corporation Biaryl acetylenes as inhibitors of matrix metalloproteases
US5932577A (en) 1996-05-15 1999-08-03 Bayer Corporation Substituted oxobutyric acids as matrix metalloprotease inhibitors
JP2002515744A (ja) 1996-05-20 2002-05-28 シグナル ファーマシュウティカルズ，インコーポレイテッド マイトジェン活性化プロテインキナーゼｐ３８―２およびその使用方法
PT1021424E (pt) 1996-06-21 2003-06-30 Upjohn Co Amidas de tiadiazolo como inibidores da metaloproteinase de matriz
US5852213A (en) 1996-07-10 1998-12-22 American Cyanamid Company Mercaptoketones and mercaptoalcohols and a process for their preparation
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
YU1899A (sh) 1996-07-18 2000-03-21 Pfizer Inc. Inhibitori matričnih metaloproteaza na bazi fosfinata
WO1998003164A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfone metalloprotease inhibitors
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
IT1284876B1 (it) 1996-08-07 1998-05-22 Applied Research Systems Hcg come inibitore della collagenasi
CA2263154A1 (en) 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GB9616643D0 (en) 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
ES2231879T3 (es) 1996-08-16 2005-05-16 Warner-Lambert Company Llc Inhibidores de metaloproteinasas de la matriz de acido butirico.
RU2170232C2 (ru) 1996-08-28 2001-07-10 Дзе Проктер Энд Гэмбл Компани Амиды фосфиновых кислот и способ предупреждения или лечения заболевания, связанного с нежелательной активностью металлопротеазы
US6624177B1 (en) 1996-09-04 2003-09-23 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
EP0929542A1 (en) 1996-09-04 1999-07-21 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
WO1998009940A1 (en) 1996-09-04 1998-03-12 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6022948A (en) 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
CA2266478C (en) 1996-09-23 2002-11-12 Focal, Inc. Polymerizable biodegradable polymers including carbonate or dioxanone linkages
NZ334729A (en) 1996-09-27 2001-01-26 Upjohn Co 'Beta'-sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors involved in tissue degradation
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5977408A (en) 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
GB9621814D0 (en) 1996-10-19 1996-12-11 British Biotech Pharm Metalloproteinase inhibitors
EP0934267B1 (en) 1996-10-22 2002-01-30 PHARMACIA & UPJOHN COMPANY Alpha-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
MY117687A (en) 1996-10-31 2004-07-31 Bayer Corp Substituted 4-biphenyl-4-hydroxybutric acid derivatives as matrix metalloprotease inhibitors
JPH10130217A (ja) 1996-11-01 1998-05-19 Kotobuki Seiyaku Kk カルボン酸及びその誘導体及びその製造法並びにこれを含有する医薬組成物
US5965441A (en) 1996-11-13 1999-10-12 The General Hospital Coporation HSV/AAV hybrid amplicon vectors
EP1707631A3 (en) 1996-11-20 2006-12-27 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
MXPA99001974A (es) 1996-12-09 2002-03-27 Warner Lambert Co Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular.
ZA9711121B (en) 1996-12-13 1998-06-23 Handelman Joseph H Reduction of hair growth.
DE69727695T2 (de) 1996-12-17 2005-02-10 Warner-Lambert Co. Llc Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
EP0948489A1 (en) 1996-12-17 1999-10-13 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
US5985911A (en) 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US6153436A (en) 1997-01-10 2000-11-28 The Board Of Trustees Of The University Of Arkansas Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions
JP2001509810A (ja) 1997-01-17 2001-07-24 ファルマシア・アンド・アップジョン・カンパニー Ｍｍｐインヒビターとしてのビス−スルホンアミドヒドロキサム酸
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
WO1998035022A1 (en) 1997-02-06 1998-08-13 Osiris Therapeutics, Inc. p21?CIP1 OR p27KIP1¿ EFFECTS ON THE REGULATION OF DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELLS
WO1998036742A1 (en) 1997-02-25 1998-08-27 The Regents Of The University Of Michigan Methods and compositions for preventing and treating chronological aging in human skin
US6197791B1 (en) 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
CN1254337A (zh) 1997-03-04 2000-05-24 孟山都公司 N－羟基4－磺酰基丁酰胺化合物
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039329A1 (en) 1997-03-04 1998-09-11 Monsanto Company Amidoaromatic ring sulfonamide hydroxamic acid compounds
US6087359A (en) 1997-03-04 2000-07-11 Getman; Daniel P. Thioaryl sulfonamide hydroxamic acid compounds
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US5932600A (en) 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US20020111495A1 (en) 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
GB9707333D0 (en) 1997-04-11 1997-05-28 British Biotech Pharm Metalloproteinase inhibitors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5756545A (en) 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
KR100556864B1 (ko) 1997-05-13 2006-03-10 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 렌티바이러스-기원 유전자 전달 벡터
US5804581A (en) 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US5932763A (en) 1997-05-15 1999-08-03 Bayer Corporation Inhibition of matrix metalloproteases by 2-(ω-arolalkyl)-4-biaryl-4-oxobutyric acids
GB9710490D0 (en) 1997-05-21 1997-07-16 British Biotech Pharm Metalloproteinase inhibitors
TWI234467B (en) 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
WO1999002704A2 (en) 1997-07-08 1999-01-21 Cold Spring Harbor Laboratory Dual specifically phosphatase and methods of use
US6482827B1 (en) 1997-07-10 2002-11-19 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
GB9714971D0 (en) 1997-07-16 1997-09-24 Cancer Res Campaign Tech Assays,therapeutic methods and means
GB9715030D0 (en) 1997-07-18 1997-09-24 British Biotech Pharm Metalloproteinase inhibitors
US6221646B1 (en) 1997-07-31 2001-04-24 Chiron Corporation Materials and methods for simplified AAV production
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6162241A (en) 1997-08-06 2000-12-19 Focal, Inc. Hemostatic tissue sealants
US5854382A (en) * 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
EP0897908A1 (de) 1997-08-19 1999-02-24 Roche Diagnostics GmbH 3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US6448058B1 (en) 1997-09-12 2002-09-10 Versicor, Inc. Methods for solid phase synthesis of mercapto compounds and derivatives, combinatorial libraries thereof and compositions obtained thereby
GB9719426D0 (en) 1997-09-13 1997-11-12 Johnson Matthey Plc Novel process
US5997895A (en) 1997-09-16 1999-12-07 Integra Lifesciences Corporation Dural/meningeal repair product using collagen matrix
WO2000000600A2 (en) 1997-09-22 2000-01-06 Chang Lung Ji Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
WO1999015641A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US6080874A (en) 1997-09-25 2000-06-27 Abbott Laboratories Synthesis and isolation of N-(aryl or heteroaryl)-alkyl-N-hydroxyurea
JPH11106775A (ja) 1997-10-03 1999-04-20 Taiho Kogyo Co Ltd 固体潤滑被膜組成物及びそれを用いた滑り軸受材料
AU9663798A (en) 1997-10-06 1999-04-27 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
CN1282319A (zh) 1997-10-09 2001-01-31 小野药品工业株式会社 氨基丁酸衍生物
EP1025102B1 (en) 1997-10-20 2004-05-19 F. Hoffmann-La Roche Ag Bicyclic kinase inhibitors
US7048929B1 (en) 1997-11-10 2006-05-23 Dana-Farber Cancer Institute, Inc. Stabilized primate lentivirus envelope glycoproteins
US6063786A (en) 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
US6187924B1 (en) 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
DE69828638T2 (de) 1997-11-12 2005-12-01 Darwin Discovery Ltd., Slough Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
TR200001391T2 (tr) 1997-11-21 2000-11-21 Pharmacia & Upjohn Company Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri.
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
AU749059B2 (en) 1997-12-12 2002-06-20 Cell Genesys, Inc. Therapeutic use of lentiviral vectors
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
HUP0100427A3 (en) 1997-12-23 2002-11-28 Warner Lambert Co Ace inhibitor-mmp inhibitor combinations
US5994099A (en) 1997-12-31 1999-11-30 The University Of Wyoming Extremely elastic spider silk protein and DNA coding therefor
NZ504683A (en) 1998-01-09 2002-06-28 Pfizer Amide derivatives and pharmaceutical compositions thereof and their use as matrix metalloprotease inhibitors
US6071903A (en) 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
GB9804504D0 (en) 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
US6169103B1 (en) 1998-03-03 2001-01-02 Warner-Lambert Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6037361A (en) 1998-03-09 2000-03-14 Warner-Lambert Company Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6100032A (en) 1998-03-13 2000-08-08 Johns Hopkins University Human Smad3 and Smad4 are sequence-specific transcription activators
FI980604A0 (fi) 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer
ES2286882T3 (es) 1998-03-27 2007-12-01 The Scripps Research Institute Composiciones de proteina de fusion de quinasa wee1, secuencias de nucleotidos, sistemas de expresion y procedimientos de uso.
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
WO1999051754A1 (en) 1998-04-02 1999-10-14 Dana-Farber Cancer Institute, Inc. Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente
ES2220004T3 (es) 1998-04-10 2004-12-01 Pfizer Products Inc. Derivados del acido ciclobutil-ariloxiarilsulfonilaminohidroxamico.
GT199900044A (es) 1998-04-10 2000-09-14 Procedimientos para preparar haluros de fenoxifenilsulfonilo.
AU3665199A (en) 1998-04-29 1999-11-16 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
JPH11313675A (ja) 1998-04-30 1999-11-16 Hoechst Marion Roussel Kk ヒトｂｍｐ−７プロモーターおよびこれを用いた骨関連物質の探索法
US6376527B1 (en) 1998-05-05 2002-04-23 Syntex (U.S.A.) Llc Pyrazole derivatives-p38 map kinase inhibitors
US20020156114A1 (en) 1998-05-05 2002-10-24 Goldstein David Michael Pyrazole derivatives - p38 MAP kinase inhibitors
US6316466B1 (en) 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
CA2331878A1 (en) 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6168807B1 (en) 1998-07-23 2001-01-02 Les Laboratoires Aeterna Inc. Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof
IL140746A0 (en) 1998-07-30 2002-02-10 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
WO2000006560A1 (en) 1998-07-30 2000-02-10 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
US6117869A (en) 1998-08-04 2000-09-12 Warner-Lambert Company Compounds for and methods of inhibiting matrix metalloproteinases
US6514534B1 (en) 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
JP2002523492A (ja) 1998-08-29 2002-07-30 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド タンパク質分解酵素阻害剤としてのヒドロキサム酸誘導体
US6509337B1 (en) 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
CA2344412A1 (en) 1998-09-21 2000-03-30 Takeda Chemical Industries, Ltd. Thiol compound, their production and use
AU1324300A (en) 1998-10-26 2000-05-15 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
EP1126843A4 (en) 1998-10-29 2005-06-15 Bristol Myers Squibb Co AMINO-CELL DERIVATIVE COMPOUNDS INHIBITORS OF ENZYME IMPDH
AU1707700A (en) 1998-10-29 2000-05-22 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
US6420403B1 (en) 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
US6210922B1 (en) 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
EP1137373A4 (en) 1998-12-04 2004-05-19 Chandrashekhar P Pathak BIOCOMPATIBLE, CROSSLINKED POLYMERS
EP1147189A2 (en) 1998-12-04 2001-10-24 Immusol, Inc. Ribozyme therapy for the treatment and/or prevention of restenosis
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6328229B1 (en) 1998-12-18 2001-12-11 Cohesion Technologies, Inc. Low volume mixing spray head for mixing and dispensing of two reactive fluid components
US6544980B2 (en) 1998-12-31 2003-04-08 Aventis Pharmaceuticals Inc. N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
US6262080B1 (en) 1998-12-31 2001-07-17 Avantis Pharmaceuticals Inc. 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
US6294539B1 (en) 1999-01-19 2001-09-25 Advanced Syntech, Llc Heterocyclic hydroxamic acid derivatives as MMP inhibitors
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
JP2002536373A (ja) 1999-02-08 2002-10-29 ジー・ディー・サール・アンド・カンパニー スルファメトヒドロキサム酸メタロプロテアーゼ阻害剤
GB9903598D0 (en) 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
CN1196687C (zh) 1999-03-19 2005-04-13 沃泰克斯药物股份有限公司 Impdh酶抑制剂
CA2366264A1 (en) 1999-04-02 2000-10-12 Bristol-Myers Squibb Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
AU4181000A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
US6569899B1 (en) 1999-04-06 2003-05-27 Ono Pharmaceuticals Co., Ltd. 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
WO2000063194A1 (en) 1999-04-19 2000-10-26 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
US7250299B1 (en) 1999-04-29 2007-07-31 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6509361B1 (en) 1999-05-12 2003-01-21 Pharmacia Corporation 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
DE60028372T2 (de) 1999-05-24 2007-05-03 Shionogi & Co., Ltd. Methode zum auswerten der in vivo matrix-metalloproteinasen hemmenden aktivität
WO2000073288A1 (en) 1999-05-28 2000-12-07 Vertex Pharmaceuticals Incorporated Method for preparing 5-substituted oxazoles
JP3362778B2 (ja) 1999-06-03 2003-01-07 独立行政法人農業生物資源研究所 結晶性絹超微粉末の製造方法
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
US6294694B1 (en) 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
CA2377278C (en) 1999-06-25 2010-03-23 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of impdh
US6541521B1 (en) 1999-07-12 2003-04-01 Warner-Lambert Company Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
KR20010010393A (ko) * 1999-07-20 2001-02-05 김윤 소수성 고분자와 친수성 고분자의 생분해성 블록 공중합체 및이를 포함하는 약물 전달체 조성물
EP1211240A4 (en) 1999-09-01 2003-02-12 Ajinomoto Kk BISCYCLOPROPANOCARBOXYLIC ACID AMIDE COMPOUNDS AND MEDICINAL USE THEREOF
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
SE9904177D0 (sv) 1999-11-18 1999-11-18 Astra Ab Novel compounds
GB9929979D0 (en) 1999-12-17 2000-02-09 Darwin Discovery Ltd Hydroxamic acid derivatives
US6380253B1 (en) 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
NZ519547A (en) 2000-01-31 2004-03-26 Pfizer Prod Inc Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
EP1252157B1 (en) 2000-01-31 2004-06-23 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
AU3838401A (en) 2000-02-17 2001-08-27 3M Innovative Properties Co Delivery systems using preformed biodegradable polymer compositions and methods
US6867299B2 (en) 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
WO2001066706A1 (en) 2000-03-03 2001-09-13 Human Genome Sciences, Inc. Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
BR0109469A (pt) 2000-03-17 2003-04-29 Bristol Myers Squibb Co Compostos derivados de b-aminoácidos, composição farmacêutica, método para o tratamento ou prevenção de disfunções inflamatórias, método para o tratamento de condições ou doenças mediadas por mmps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso do composto
CA2404384A1 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
US20020019539A1 (en) 2000-03-31 2002-02-14 Bailey Anne E. Process for the preparation of matrix metalloproteinase inhibitors
AU4888401A (en) 2000-04-07 2001-10-23 Samsung Electronics Co., Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
JP2003532643A (ja) 2000-04-13 2003-11-05 フアーマセツト・リミテツド 肝炎ウイルス感染症を治療するための３’−または２’−ヒドロキシメチル置換ヌクレオシド誘導体
WO2001081340A2 (en) 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles that are inhibitors of impdh enzyme
US6503892B2 (en) 2000-04-26 2003-01-07 New England Medical Center Hospitals Inc. Method of using matrix metalloproteinase inhibitors in filtering blebs following glaucoma filtering surgery and in the treatment of ischemic damage to the retina and optic nerve
JP2004514409A (ja) 2000-05-10 2004-05-20 ブリストル−マイヤーズ　スクイブ　カンパニー 修飾イノシン５’−一リン酸デヒドロゲナーゼポリペプチドおよびその用途
EP1286994A1 (en) 2000-05-15 2003-03-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
CN1443190A (zh) 2000-07-18 2003-09-17 里奥制药有限公司 基质金属蛋白酶抑制剂
KR20030040415A (ko) 2000-08-22 2003-05-22 리버팜 인크. 질병의 치료시에 특이성을 향상시키는 방법
EP1315727B1 (en) 2000-08-31 2005-06-29 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6455570B1 (en) 2000-10-06 2002-09-24 The Trustees Of The University Of Pennsylvania Polypyrrolinone based inhibitors of matrix metalloproteases
US20020151491A1 (en) 2000-11-28 2002-10-17 Jian-Dong Li Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC
OA12588A (en) 2000-12-15 2006-06-08 Triangle Pharmaceuticals Inc DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor.
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
EP1355648A2 (en) 2001-01-11 2003-10-29 Bristol-Myers Squibb Pharma Company 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a)
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
ES2248231T3 (es) 2001-01-31 2006-03-16 Pfizer Products Inc. Derivados de eteres utiles como inhibidores de las isozimas pde4.
PL364135A1 (en) 2001-01-31 2004-12-13 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
CZ20031903A3 (cs) 2001-01-31 2004-07-14 Pfizer Products Inc. Amidové deriváty thiazolyl-, oxazolyl-, pyrrolyl- a imidazolyl karboxylových kyselin užitečné jako inhibitory isozymů PDE4
KR100639772B1 (ko) 2001-02-12 2006-10-30 에프. 호프만-라 로슈 아게 6-치환된 피리도-피리미딘
MXPA01013171A (es) 2001-02-14 2004-05-21 Warner Lambert Co Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz.
MXPA01013172A (es) 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
AU2002240755B2 (en) 2001-03-13 2007-07-05 Angiotech International Ag Micellar drug delivery vehicles and uses thereof
AU2002338286A1 (en) 2001-04-10 2002-10-28 Leo Pharma A/S Novel aminophenyl ketone derivatives
CA2445239C (en) * 2001-04-25 2012-08-21 Eidgenossische Technische Hochschule Zurich Drug delivery matrices to enhance wound healing
US20030166201A1 (en) 2001-04-30 2003-09-04 Jensen Michael C. Selection systems for genetically modified cells
AU2002257456A1 (en) 2001-05-24 2002-12-03 University Of Western Ontario Control of myogenesis by modulation of p38 map kinase activity
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
US20030100031A1 (en) 2001-06-11 2003-05-29 Steven Dower Integrative assays for monitoring molecular assembly events
CA2450159A1 (en) 2001-06-15 2002-12-27 National Research Council Of Canada Methods for modulating gap junctions
GB0117506D0 (en) 2001-07-18 2001-09-12 Bayer Ag Imidazopyridinones
WO2003016248A2 (en) 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
EP1423378B1 (en) 2001-08-30 2005-11-09 F. Hoffmann-La Roche Ag Aminopyrrole compounds as antiinflammatory agents
US6740649B2 (en) 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
WO2003031431A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
US20030105073A1 (en) 2001-10-23 2003-06-05 Haughan Alan Findlay Quinolone derivatives
CN1578665A (zh) 2001-10-31 2005-02-09 默克专利股份公司 4型磷酸二脂酶抑制剂及其应用
WO2003040103A1 (en) 2001-11-02 2003-05-15 Bristol-Myers Squibb Company β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
PL369738A1 (en) 2001-11-05 2005-05-02 Merck Patent Gmbh Hydrazono-malonitriles
AU2002365436B8 (en) 2001-11-09 2008-04-03 Intarcia Therapeutics, Inc. Method for treating diseases with omega interferon
AU2002352444A1 (en) 2001-12-20 2003-07-09 Celltech R And D Limited Quinazolinedione derivatives
AU2002346729A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
AU2002357312A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
CN1697647A (zh) 2002-02-01 2005-11-16 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
AU2003230692A1 (en) 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
WO2003082287A1 (en) 2002-03-22 2003-10-09 Bristol-Myers Squibb Company Dpc 333 formulation having unique biopharmaceutical characteristics
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
GB0208223D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
US6620813B1 (en) 2002-06-21 2003-09-16 Medinox, Inc. Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
WO2004044223A2 (en) 2002-11-12 2004-05-27 Enzon Pharmaceuticals, Inc. Prodrugs of vancomycin with hydrolysis resistant polymer linkers
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062827A2 (en) * 1999-04-16 2000-10-26 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition

Also Published As

Publication number Publication date
WO2004060346A2 (en) 2004-07-22
AU2003300076A1 (en) 2004-07-29
US20120252905A1 (en) 2012-10-04
CA2511521A1 (en) 2004-07-22
US20040225077A1 (en) 2004-11-11
AU2003300076B2 (en) 2009-07-30
DE60331367D1 (de) 2010-04-01
WO2004060346A3 (en) 2004-11-04
EP2181704A3 (en) 2011-08-17
ATE457716T1 (de) 2010-03-15
JP2011173887A (ja) 2011-09-08
CA2511521C (en) 2012-02-07
US20090192214A1 (en) 2009-07-30
EP2181704A2 (en) 2010-05-05
EP1594459A2 (en) 2005-11-16
JP2006516548A (ja) 2006-07-06
US9326934B2 (en) 2016-05-03
EP2181704B1 (en) 2015-05-06
HK1083067A1 (en) 2006-06-23
EP1594459B1 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
AU2003300076C1 (en) Drug delivery from rapid gelling polymer composition
KR100974733B1 (ko) 가교된 생합성물질을 형성하기 위한 조성물 및 시스템, 및이와 관련된 제조 및 사용 방법
US20040219214A1 (en) Tissue reactive compounds and compositions and uses thereof
US9353218B2 (en) Kit for multifunctional compounds forming crosslinked biomaterials
CA2536181A1 (en) Polymer compositions and methods for their use
JP2007513650A (ja) 移植可能なセンサーおよび移植可能なポンプならびに瘢痕化抑制剤
JP2006525855A (ja) 吻合接合装置
CN1756530A (zh) 从快速凝胶化聚合物组合物进行药物传递
HK1083067B (en) Drug delivery from rapid gelling polymer composition
MXPA06012496A (en) Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 OCT 2009.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 OCT 2009

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired